Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 5Neoplasm Metastasis 3Stomach Neoplasms 2Advanced Solid Tumors 2Urinary Bladder Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Triple Negative Breast Neoplasms 1Solid Tumors 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Adenocarcinoma of the Stomach 1

Interventions

Fluorouracil 21Oxaliplatin 17Leucovorin 17Bevacizumab 17Irinotecan 13Panitumumab 12Cetuximab 12IFL protocol 9Capecitabine 9pembrolizumab 7Radiotherapy 7Pemetrexed 5Gemcitabine 5labetuzumab 3conatumumab 3Cisplatin 3Carboplatin 3Albumin-Bound Paclitaxel 35,11-methenyltetrahydrohomofolate 3130-nm albumin-bound paclitaxel 3vatalanib 2trametinib 2spartalizumab 2pegfilgrastim 2ganitumab 2encorafenib 2dostarlimab 2Ramucirumab 2Paclitaxel 2Melphalan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Rectal Neoplasms × tesetaxel × Clear all
NCT00080834 2012-05-16

DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma

Daiichi Sankyo

Phase 2 Completed
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡